Processing

Please wait...

Settings

Settings

Goto Application

1. WO2006100679 - RECOMBINANT ANTIBODIES AGAINST HUMAN TYPE II TRANSGLUTAMINASE AND USES THEREOF

Publication Number WO/2006/100679
Publication Date 28.09.2006
International Application No. PCT/IL2006/000368
International Filing Date 22.03.2006
IPC
C07K 16/40 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
40against enzymes
A61K 39/395 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
C12N 15/13 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
12Genes encoding animal proteins
13Immunoglobulins
CPC
A61K 2039/505
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
505comprising antibodies
A61K 48/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
C07K 16/40
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
40against enzymes
C07K 2317/21
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
20characterized by taxonomic origin
21from primates, e.g. man
C07K 2317/52
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
50characterized by immunoglobulin fragments
52Constant or Fc region; Isotype
C07K 2317/622
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
60characterized by non-natural combinations of immunoglobulin fragments
62comprising only variable region components
622Single chain antibody (scFv)
Applicants
  • QUARK PHARMACEUTICALS, INC. [US]/[US] (AllExceptUS)
  • QBI ENTERPRISES LTD. [IL]/[IL] (BA)
  • MARZARI, Roberto [IT]/[IT] (UsOnly)
  • SBLATTERO, Daniele [IT]/[IT] (UsOnly)
Inventors
  • MARZARI, Roberto
  • SBLATTERO, Daniele
Common Representative
  • QBI ENTERPRISES LTD.
Priority Data
60/664,23822.03.2005US
60/689,00608.06.2005US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) RECOMBINANT ANTIBODIES AGAINST HUMAN TYPE II TRANSGLUTAMINASE AND USES THEREOF
(FR) ANTICORPS DE RECOMBINAISON DIRIGES CONTRE LA TRANSGLUTAMINASE HUMAINE DE TYPE II ET UTILISATIONS DE CES ANTICORPS
Abstract
(EN)
The present invention provides specific antibodies that are able to inhibit TGase II enzymatic activity. The present invention further provides a pharmaceutical composition comprising as an active ingredient the antibody of the invention useful in treating or preventing fibrosis diseases, scarring, or fibrosis-related pathologies. The pharmaceutical composition may be useful for treating both acute and chronic forms of fibrosis of organs.
(FR)
La présente invention se rapporte à des anticorps spécifiques qui sont capables d'inhiber l'activité enzymatique de la TGase II. La présente invention se rapporte également à une composition pharmaceutique comportant en tant qu'ingrédient actif un anticorps tel que celui décrit ci-dessus, qui est utile pour le traitement ou la prévention des maladies de type fibrose, des troubles de cicatrisation ou des pathologies associées à des fibroses. Une telle composition pharmaceutique peut s'avérer utile pour traiter à la fois des formes aiguës et chroniques de fibroses d'organes.
Also published as
EP6711341
Latest bibliographic data on file with the International Bureau